Boston Heart Lab Named 'Most Promising Early Stage Company' 2009 by Silicom Ventures

Boston Heart Lab Named 'Most Promising Early Stage Company' 2009 by Silicom
Ventures

FRAMINGHAM, Mass., June 29 /PRNewswire/ -- Boston Heart Lab, a pioneer in
specialized diagnostics for patients with heart disease, was named "Most
Promising Early Stage Company" by Silicom Ventures at the angel investment
organization's 2009 Investment Summit, which took place June 2-3, 2009, at
Stanford University in California. A four-judge panel selected Boston Heart
Lab after evaluating the 20 participating companies for quality of management,
vision, execution abilities, and the potential scope of the opportunities.
Boston Heart Lab Chief Executive Officer, Wolfgang Daum, Ph.D., accepted the
award on behalf of the start-up company, which has seen strong revenues since
it began clinical operations in August 2008.

"We're very honored to receive this prestigious award, which is a testament
both to the important work our Boston Heart Lab team has done to develop and
launch our advanced cardiovascular diagnostic and lipid-testing program, and
to the relevance of the services we provide to the marketplace," said Dr.
Daum. "While there are other providers of esoteric testing for cardiology, we
employ the most-advanced technology available with our proprietary
two-dimensional gel electrophoresis of HDL particles and plasma sterol
analysis. We deliver clinicians a more complete picture of the patient's
health status -- our test results and analyses are the critical building
blocks for a personalized treatment plan designed to offer patients the best
opportunity for improved health outcomes. This includes more than 35
proprietary tests to assess the patient's cardiac health and risk profile, and
a treatment algorithm (Boston Heart Navigator) based on the latest
peer-reviewed scientific data."

Commenting on the award, Silicom Ventures' Founder and Managing Director, Gadi
Behar, said, "The 2009 Investment Summit showcased 20 impressive early-stage
companies in various fields -- from alternative energy and social networking
to life sciences. The four-judge panel was unanimous in choosing Boston Heart
Lab for its top award in recognition of the start-up's early success in
turning the promise of personalized medicine into a reality for cardiac
patients. There are 19 million people in the U.S. alone with established heart
disease (patients who have had heart attack or stroke) that could benefit from
Boston Heart Lab's services, not to mention the 45 million at-risk for cardiac
disease. Boston Heart Lab's work will become increasingly important as our
healthcare system focuses more and more on outcomes-based medicine to save
health dollars and improve outcomes for patients." The judges for the award
were three angel investors with extensive investment experience and a venture
capitalist partner from Claremont Creek Ventures.

About Silicom Ventures (www.silicomventures.com)
Silicom Ventures is one of the leading angel investment organizations in the
United States. It links experienced investors (high-tech executives) and
venture capitalists with entrepreneurs from around the globe and helps
individual angels pool their efforts to gain access to better ventures and
better investment deals. Silicom Ventures is leveraging its large network of
investors, venture capitalists, industry executives, and technology experts
offering entrepreneurs a highly effective screening and early funding process.
Beyond funding, Silicom Ventures connects qualified companies with potential
business partners, employers, and employees, and technical, professional, and
business advisors.

About Boston Heart Lab (www.bostonheartlab.com)
Boston Heart Lab enables cardiologists and other clinicians to prescribe
personalized treatment plans for cardiovascular disease and lipid disorders
that offer patients the best opportunity for improved health outcomes, based
on a panel of tests that provides the most comprehensive assessment available
detailing the cause and state of the patient's disease. The company's
proprietary two-dimensional gel electrophoresis of HDL particles reveals the
entire reverse cholesterol metabolism (HDL) to sub classify the disease; while
its proprietary plant sterol analysis evaluates how well the patient produces
and absorbs cholesterol. Boston Heart Lab currently offers more than 35
proprietary, state-of-the-art tests to assess the patient's cardiac health and
risk profile, and a treatment algorithm for developing a tailored treatment
protocol (Boston Heart Navigator) based on the latest peer-reviewed scientific
data. A privately held company, Boston Heart Lab began clinical operations
after receiving its CLIA license in July 2008.

Media Contact: Caroline Grossman - 781.771.5579 - caroline.grossman@gmail.com

Company Contact: Wolfgang Daum - 978-273-8266 - wdaum@bostonheartlab.com

SOURCE Boston Heart Lab

Media, Caroline Grossman, +1-781-771-5579, caroline.grossman@gmail.com, or
Company: Wolfgang Daum, +1-978-273-8266, wdaum@bostonheartlab.com